Study results published in the New England Journal of Medicine reported that the Threshold Suspend feature of a sensor-augmented insulin pump from Medtronic safely reduces nocturnal hypoglycemia. Threshold Suspend is the first-of-its-kind automated insulin pump feature unique to an investigational MiniMed integrated system which automatically suspends insulin delivery temporarily when sensor glucose values reach a pre-set low level. It is also an important step toward Medtronic’s ultimate goal to develop a fully automated artificial pancreas for people with diabetes.
The first-of-its-kind Threshold Suspend feature, exclusive to MiniMed insulin pumps, works by suspending insulin delivery for up to two hours when an individual’s sensor glucose value reaches a preset low sensor level. Once the threshold is met, the insulin pump will alarm and suspend all insulin delivery for two hours. Insulin delivery can be resumed by the patient at any time.
The feature is commercially available internationally in the MiniMed Veo System (where the feature is called Low Glucose Suspend). Threshold Suspend is also a part of the MiniMed 530G, which is not commercially available in the U.S. at this time, and is currently under review at the FDA. The MiniMed 530G system is the first system submitted for approval under the new product classification, ‘OZO: Artificial Pancreas Device System, Threshold Suspend,’ created by the U.S. Food and Drug Administration.
This news item first appeared in our free-to-receive online magazine. Go to the home page of this website to sign up – we just need your email address.
